RB1 and cancer: RB expression can be used to predict sensitivity of cancer cells to antimitotic and cytotoxic chemotherapies (12, 16), and recent evidence suggests that CDK4/6 inhibitors can be used to suppress the DNA damage response in RB-dependent cancers (24).